REPLIGEN CORP [RGEN] - / BioLife Solutions merger
Repligen Corp will acquire BioLife Solutions, Inc. for $11.25 in cash and 0.1442 shares of Repligen's common stock per share of BioLife common stock.
Why this matters
Repligen Corp, a leading provider of technologies for biologics manufacturing, has announced a definitive agreement to acquire BioLife Solutions, Inc., a company known for its biopreservation media platform and cell processing tools. This acquisition is strategically aimed at expanding Repligen's presence in the rapidly growing cell therapy market and enhancing its offerings to cell therapy customers. The transaction, valued at approximately $1.5 billion, will be executed with 64% of the consideration in Repligen common stock and 36% in cash. The boards of both companies have unanimously approved the deal, which is subject to customary closing conditions.